Projects

Deputy Scientific Director of INPP
RNDr. Martina Cebová, PhD.

National

Current
  • Effects of mesenchymal stem cells and HMGB1 inhibitor on cardiovascular system after experimentally induced myocardial infarction in hypertension and diabetes mellitus
    Program: SRDA
    Duration: 1. 7. 2023 – 30. 6. 2027
  • The role of inflammation in the development of cardiovascular complications associated with metabolic syndrome and prediabetes
    Program: SRDA
    Duration: 1. 7. 2022 – 30. 6. 2025
Finished
  • The effect of aging and hypertension on experimental myocardial infarction
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2023
  • New perspectives in the treatment of cardiovascular complications associated with COVID-19
    Program: SRDA
    Duration: 16. 9. 2020 – 31. 12. 2021
  • The effect of STAT1 and ISG15 inhibitors on biochemical and morphological parameters in experimental myocardial infarction
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2019
  • Interaction of nitrergic, neurotrophic and endocrine signaling in the etiopathogenesis of schizophrenia
    Program: SRDA
    Duration: 1. 7. 2015 – 30. 6. 2019
  • Cardiovascular Effects of Nanoencapsulated Simvastain and Coenzyme Q10 in Experimental Hyperlipidemia (KANASTA)
    Program: Other projects
    Duration: 27. 11. 2015 – 26. 11. 2018
  • The efect of nitric oxide and hydrogen sulfide on structure and function of cardiovascular system in normotenzive and hypertenzive rats.
    Program: VEGA
    Duration: 1. 1. 2013 – 31. 12. 2016
  • Participation of HMGB1 in experimental myocardial infarction: cardioprotection vs. cardiac depression
    Program: VEGA
    Duration: 1. 1. 2014 – 31. 12. 2016
  • The participation of neuronal NO synthase in the regulation of function and structure in cardiovascular system of normotensive and spontaneouly hypertensive rats.
    Program: VEGA
    Duration: 1. 1. 2010 – 31. 12. 2013
  • Etiopatogenesis of compromise blood pressure control: manifestation on structure and function of cardiovascular system.
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2012
  • Investigation of preventive effect of vasoactive substances on development of structure and function of cardiovascular system in SHR as an experimental model of humen essential hypertension
    Program: VEGA
    Duration: 1. 1. 2006 – 1. 12. 2008
  • Effects of mesenchymal stem cells and HMGB1 inhibitor on cardiovascular system after experimentally induced myocardial infarction in hypertension and diabetes mellitus
    Program: SRDA
    Duration: 0. 0. 0000 – 0. 0. 0000
Employees